Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant Therapy (ELPIS)
Omission of Surgery and Sentinel Lymph Node Dissection in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant Therapy
Sponsor: Fundacio Clinic Barcelona
Terminated
The study was prematurely halted primarily due to low patient accrual. Despite efforts to optimize recruitment, the enrollment rate remained insufficient to meet the predefined targets, and continuation was deemed unfeasible
Other HER2-positive Breast Cancer trials with similar outcome
A PHASE2 clinical study on HER2-positive Breast Cancer and Stage I Breast Cancer, this trial is terminated or withdrawn. The trial is conducted by Fundacio Clinic Barcelona and has accumulated 8 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Feb 2026 — Present [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Sep 2024 — Feb 2026 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE2
-
Feb 2022 — Jun 2024 [monthly]
Recruiting PHASE2
▶ Show 3 earlier versions
-
May 2021 — Feb 2022 [monthly]
Recruiting PHASE2
-
Jan 2021 — May 2021 [monthly]
Recruiting PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE2
First recorded
Sep 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Fundacio Clinic Barcelona
- Roche Pharma AG
- SOLTI Breast Cancer Research Group
For direct contact, visit the study record on ClinicalTrials.gov .